The Editors highlight three aspects of OMB’s recently proposed rule changes as particularly striking: that decisions on research funding would be made by political appointees, that funding could ...

Though Medicare is launching the GLP-1 Bridge program, offering enrollees temporary discounted access to GLP-1 medications ...

Explore this issue of The New England Journal of Medicine (Vol. 392 No. 21).

When patients who have become homeless show a physician photos of themselves in better times, they are, in part, asking to be treated fairly, like they are people who might still turn their lives ...

In 832 patients with rare genetic disease, a conclusive diagnosis was made for 160 patients (19.2%) with long-read genome sequencing and for 137 patients (16.5%) with standard-of-care testing.

Hereditary angioedema is a rare and potentially life-threatening genetic condition characterized by recurrent and debilitating swelling attacks. Lonvoguran ziclumeran (lonvo-z) — an investigational, ...

Explore this issue of The New England Journal of Medicine (Vol. 394 No. 23).

A 47-year-old man with heart failure with a reduced ejection fraction and an ICD for the primary prevention of sudden cardiac death presented with an unheralded syncopal event, which had been captured ...

Trainees’ paths to safe, independent practice are variable. Artificial intelligence could help accelerate implementation of competency-based medical education to support individualized development.

Many countries rely on air-quality indices to inform the public and help protect people during short-term increases in air pollution. Their use has important societal and economic implications.

Current therapies offer limited benefit for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is the key driver of PDAC, with ...

Talquetamab, a bispecific antibody targeting GPRC5D and CD3, has led to durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma in phase 1–2 trials, with a ...